Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Core Viewpoint - Condor Energies Inc. has successfully drilled its first horizontal well, Andakli-23, in Uzbekistan, achieving significant production increases and planning further drilling activities in the region [1][5]. Group 1: Well Performance and Production - The Andakli-23 horizontal well reached a total depth of 3,775 meters, including 1,007 meters of open hole horizontal section, and has increased average daily production to 11,844 barrels of oil equivalent per day (boepd) over the past three days [1][2]. - The well is expected to be placed on production in December 2025 after flow testing [2]. - Recent workovers in the North Syuzma field have also shown strong gas flow, with production rates reaching 9,978 boepd in the third quarter of 2025 [6]. Group 2: Technical Insights and Future Plans - The drilling operations included a vertical pilot hole that evaluated the prospectivity of the Jurassic clastics, identifying fair to good reservoir quality with estimated porosities of 9 to 13% [3]. - The company plans to drill up to 12 new wells in 2026, with the next horizontal well targeting a different carbonate reservoir [5][6]. - The successful introduction of new technologies and techniques during the drilling of A-23 is expected to enhance future production capabilities [5].

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with significant unmet medical needs [4] Group 1: Company Overview - Chemomab is developing nebokitug, a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [4] - Nebokitug has shown a favorable safety profile and has been well-tolerated in clinical and preclinical studies, with potential applications in multiple severe fibro-inflammatory diseases [4] - The company has reported positive results from five clinical trials of nebokitug, particularly from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [4] - Chemomab is preparing to initiate a Phase 3 trial for nebokitug in PSC, which is designed as a single pivotal trial with a clear pathway to regulatory approval [4] - Nebokitug has received Orphan Drug and Fast Track designations from the FDA and EMA for the treatment of PSC [4] Group 2: Upcoming Events - Co-founder and CEO Adi Mor will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City [1][3] - Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendees during the summit [2][3]

Hong Kong, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Abits Group Inc (the “Company”) (NASDAQ: ABTS), a digital data center operator specializing in bitcoin self-mining operations, today announced the results of its 2025 Annual Meeting of Shareholders held on November 21, 2025 in Hong Kong. At the meeting, the shareholders: ●Elected Conglin (Forrest) Deng, Lionel Choong Khuat Leok, Tao Xu, Chuan Zhan, and Yanyan Sun to its Board of Directors; and ●Ratified the appointment of Audit Alliance LLP as the Company’s inde ...

Core Insights - Ceribell, Inc. has received FDA 510(k) clearance for its Clarity algorithm, making it the first and only AI-powered EEG technology for detecting electrographic seizures in patients from pre-term neonates to adults [1][3] Group 1: Product and Technology - The Ceribell System combines proprietary algorithms with specialized hardware to enable real-time detection of non-convulsive seizures in neonatal patients, facilitating rapid diagnosis and treatment [3] - The FDA clearance was supported by EEG data from over 700 patients, representing the largest validation dataset for a neonatal seizure detection system [3] Group 2: Market Need and Impact - Early detection of seizures is critical in neonatal care, with approximately 9% of NICU patients diagnosed with seizures, while up to 90% may go undetected without EEG monitoring [2] - High-risk newborns who experience prolonged seizures have an 8-fold increased risk of poor outcomes, including mortality and long-term disability [2] - Recent guidelines recommend continuous EEG monitoring for neonates at high risk for seizures, highlighting the need for timely intervention [2] Group 3: Company Vision and Leadership - The CEO of Ceribell emphasized the importance of timely and accessible seizure detection for newborns, aiming to reduce delays and improve outcomes [4] - The Medical Director of Neonatal ECMO at Stanford Children's Hospital noted the lack of 24/7 EEG access in many NICUs, underscoring the need for faster, more accessible tools for evaluating brain activity [4] Group 4: Company Overview - Ceribell is focused on transforming the diagnosis and management of serious neurological conditions, with its system currently utilized in intensive care units and emergency rooms across the U.S. [7] - The company is headquartered in Sunnyvale, California, and aims to address unmet needs in acute care settings through its innovative EEG platform [7]

EL MONTE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Larry Wu, it’s Founder and Chief Executive Officer, and Erica Wei, its Chief Financial Officer, will conduct one-on-one meetings with investors at the 2025 UBS Global Technology and AI Conference, being held from December 1 through December 4 in Scottsdale, Arizona. To schedule a m ...

The company’s AI Event Trading Desk prices and trades Polymarket prediction markets with EBZT capital in search of scalable, hedged trading profitsJacksonville, FL, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Everything Blockchain Inc. (OTC: EBZT), a public AI development lab for digital asset markets, today announced the launch of an AI Event Trading Desk that uses company capital to price and trade prediction markets on Polymarket. The desk is built to turn mispriced odds on real world events, including elections, ...

Core Viewpoint - American Hotel Income Properties REIT LP (AHIP) has completed its normal course issuer bid (NCIB) and automatic securities purchase plan (ASPP), purchasing approximately 10% of its public float [1][2]. Group 1: NCIB and ASPP Details - AHIP purchased a total of 7,521,189 units under the NCIB and ASPP at a weighted average price of Cdn$0.43 per unit [2]. - The total outstanding units of AHIP currently stand at 71,890,348 [2]. - AHIP plans to apply for the renewal of its NCIB and ASPP for an additional twelve months, from December 30, 2025, to December 29, 2026, pending approval from the Toronto Stock Exchange [2]. Group 2: Company Overview - AHIP is a limited partnership focused on investing in hotel real estate properties across the United States, primarily in premium branded, select-service hotels located in secondary metropolitan markets [3]. - The hotels operate under brands affiliated with Marriott, Hilton, and IHG Hotels through license agreements [3]. - The long-term objectives of AHIP include increasing the value of its hotel properties through operational excellence, active asset management, and capital expenditures, as well as enhancing unitholder value and distributions [3].

Core Insights - Xcel Brands, Inc. announces a partnership between Longaberger and Shannon Doherty to launch a new home collection that emphasizes warmth, style, and functionality [2][3] Company Overview - Xcel Brands, Inc. is a media and consumer products company focused on influencer-driven brands through social commerce and livestreaming, with a portfolio that includes Halston, Judith Ripka, and Longaberger [6] - The company has generated over $5 billion in retail sales via livestreaming and interactive television, reaching over 43 million social media followers and broadcasting into 200 million households [6] Partnership Details - The collaboration between Longaberger and Shannon Doherty aims to blend American craftsmanship with a family-centered lifestyle, celebrating everyday living and creating a modern vision for the home [3][5] - Each product in the new collection will reflect Longaberger's handcrafted quality combined with Shannon's warmth and approachability, focusing on cozy entertaining and functional storage [5] Brand Background - Longaberger, founded in 1973, is known for its artisanal handcrafted products, particularly handmade maple baskets, and has a loyal customer base [7] - Shannon Doherty, founder of At Home with Shannon, shares home décor ideas and family routines, reaching millions through her lifestyle platform [8]

Core Insights - Soleno Therapeutics, Inc. is participating in the Piper Sandler 37 Healthcare Conference on December 4, 2025, with CEO Anish Bhatnagar scheduled for a fireside chat [1] Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [3] - The company's first commercial product is VYKAT™ XR (diazoxide choline) extended-release tablets, designed for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [3]